Hints and tips:
...BlackRock did not support Bluebell on resolutions at Glencore and Solvay. This article has been amended to correct the market capitalisation of BlackRock...
...A study by academics at Solvay Brussels School of Economics, Stockholm School of Economics and Harvard Law School revealed that when a divestment tweet went viral, the market value of big carbon emitters...
...They said BlackRock failed to support Bluebell’s position on environmental shareholder resolutions at mining and commodities group Glencore and chemicals group Solvay....
...Among the recipients were chemicals groups Solvay and Orbia, which plan to construct a $850mn polyvinylidene fluoride plant in Georgia by 2026....
...Bluebell’s frustrated that BlackRock didn’t support its position on environmental shareholder resolutions at other companies, such as Glencore and Solvay, and has decided to go after the world’s largest...
...A version of this article was first published by Nikkei Asia on July 27. ©2022 Nikkei Inc. All rights reserved....
...Solvay is carving out its cash-generating soda ash business used in glass and detergents, which accounts for slightly more than 60 per cent of the group’s CO2 emissions, as the Belgian group simplifies its...
...I teach business strategy at a university [Solvay business school in Belgium]. It is something I love....
...Also on board were the US heads of the European groups BASF, Novo Nordisk, Shell, Solvay Chemicals and Zurich Insurance, as well as leaders from Mahindra of India, Samsung of South Korea, Japan’s Panasonic...
...In the US, the debate has advanced to the Supreme Court, where the judges are currently scrutinising a case brought by the FTC against Solvay, part of AbbVie and producer of the testosterone product AndroGel...
...The ruling provides a fresh twist to a dispute over efforts by Solvay, now part of AbbVie, to delay cut price versions of its AndroGel product following payments to generic rivals including Actavis....
...Earnings failed to impress investors, with shares in Belgian chemicals group Solvay falling 2.5 per cent to €108.65, even after beating annual profit expectations....
...Alexa Joyce is an MBA graduate of Solvay Brussels School of Economics and Management, which she attended in 2000....
...Solvay, the Belgian chemical company, is a significant shareholder in Acal Energy....
...“The FTA will only translate into a few percentage point gains, but that could be enough to make a difference in the price war against China,” says André Nothomb, representative of Solvay, a Belgian chemical...
...was not “knee-jerk” but had been under consideration for several years and accelerated following the integration and internal separation within the group of the two divisions following its acquisition of Solvay...
...Earlier this year, Solvay of Belgium announced a €3.4bn bid for French rival Rhodia....
...Solvay is just trying to improve a painfully flabby financial structure....
...Belgian drug and chemicals group Solvay climbed 3.1 per cent to €111.60 after UBS raised its rating to “buy” from “neutral”....
...“Solvay, pro forma for the acquisition, now offers attractive late-cyclical growth boosted by restructuring and at an inexpensive valuation,” the broker said....
...Solvay, the Belgian chemical company, rose to its highest since October 2008 after reporting growing demand and rising fourth-quarter operating profit. Its shares rose 4.8 per cent to €84.17....
...Chemicals companies Croda International , up 1.4 per cent to £17.18, and Elementis , 4.1 per cent stronger at 156p, were in demand after France’s Rhodia recommended a €3.4bn cash offer from Solvay....
...competition now means new funds can often make a high double-digit return in a couple of months from even the most mainstream deals, such as the €4.5bn ($5.8bn) takeover by Abbott Laboratories of the US of Solvay...
...Many companies have sealed deals to expand through acquisitions – such as Abbott’s purchase of Solvay, a European company with a strong presence in emerging markets....
...For Abbott, the Piramal transaction comes less than a year after it acquired the Belgium-based drugmaker Solvay for €4.5bn ($5.6bn), and follows the announcement last week of two collaboration agreements...
International Edition